AstraZeneca partners with Absci for AI-driven cancer antibody

Reuters

AstraZeneca has signed a deal with Absci worth up to $247 million to design an antibody for cancer treatment using AI technology. The collaboration aims to utilize Absci's AI for large-scale protein analysis. The deal includes an upfront fee, research funding, milestone payments, and royalties. Absci's CEO highlighted the potential for success and reduced development time through AI in drug discovery. (Words: 65)


With a significance score of 7.1, this news ranks in the top 1% of today's 29722 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 9500 minimalists.